Arnold & Porter Represents ESTEVE in its Entry into an Agreement to Acquire TerSera IST Unit

Arnold & Porter recently advised ESTEVE in its entry into an agreement to acquire TerSera Therapeutics LLC’s Infusion Specialty Therapies (IST) business unit. This strategic acquisition enables ESTEVE to expand its U.S. presence, with two highly specialized on-market assets, Prialt^® (ziconotide intrathecal infusion) and Quzyttir^® (cetirizine hydrochloride injection), and a dedicated team of sales, marketing and medical professionals.

With this transaction, ESTEVE will obtain worldwide rights for Quzyttir^® in all territories (except for China) and consolidates its rights for Prialt^® worldwide.

The transaction is expected to close in the first quarter of 2026, subject to regulatory clearances.

The Arnold & Porter team included partners Tracy Belton and Jeremy Willcocks, and senior associates Wayne Janke and Alexus Williams. Partners Kristin Hicks and Liz Lindquist and senior associates Sunha Cha, Phillip DeFedele, and Jonathan Trinh assisted with healthcare regulatory matters. Partners Debbie Feinstein and Bill Efron and counsel Barbara Wootton assisted with U.S. antitrust matters. Partner John Schmidt and counsel Zeno Frediani assisted with international antitrust matters. Counsel Kathleen Wechter and senior associate Kathryn Geoffroy assisted with employee benefits and labor matters. Partner Laurie Abramowitz and associate Sean Kavanaugh assisted with tax matters. Senior counsel Sheryl Gittlitz assisted with finance matters. Counsel Nancy Perkins assisted with CFIUS and data privacy matters. Partner Soo-Mi Rhee and senior associate Junghyun Baek assisted with export control and sanctions matters. Senior associate Colleen Couture and associate Alexis Sabet also assisted in the transaction.